Pancreatic safety of incretin-based drugs--FDA and EMA assessment

N Engl J Med. 2014 Feb 27;370(9):794-7. doi: 10.1056/NEJMp1314078.

Authors

Amy G Egan¹, Eberhard Blind, Kristina Dunder, Pieter A de Graeff, B Timothy Hummer, Todd Bourcier, Curtis Rosebraugh

Affiliation

¹ From the Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD (A.G.E., B.T.H., T.B., C.R.); the European Medicines Agency, London (E.B.); Läkemedelsverket, Uppsala, Sweden (K.D.); and the Dutch Medicines Evaluation Board, Utrecht, the Netherlands (P.A.G.).

PMID: 24571751
DOI: 10.1056/NEJMp1314078

No abstract available

MeSH terms

Animals
Diabetes Mellitus, Type 2 / drug therapy
Drug Approval*
Drug Evaluation, Preclinical
European Union
Humans
Hypoglycemic Agents / adverse effects*
Hypoglycemic Agents / therapeutic use
Incretins / adverse effects*
Mice
Pancreatic Neoplasms / chemically induced*
Pancreatitis / chemically induced*
Rats
United States
United States Food and Drug Administration

Substances

Hypoglycemic Agents
Incretins